Scientific article
Open access

Evasin-4, a tick-derived chemokine-binding protein with broad selectivity can be modified for use in preclinical disease models

Published inThe FEBS journal, vol. 280, no. 19, p. 4876-4887
Publication date2013

Rhipicephalus sanguineus, the common brown dog tick, produces several chemokine-binding proteins which are secreted into the host in its saliva to modulate the host response during feeding. Two of these demonstrate very restricted selectivity profiles. Here, we describe the characterization of the third, which we named Evasin-4. Evasin-4 was difficult to produce recombinantly using its native signal peptide in HEK cells, but expressed very well using the urokinase-type plasminogen activator signal peptide. Using SPR, Evasin-4 was shown to bind most CC chemokines. Investigation of the neutralization properties by inhibition of chemokine-induced chemotaxis showed that binding and neutralization did not correlate in all cases. Two major anomalies were observed: no binding was observed to CCL2 and CCL13, yet Evasin-4 was able to inhibit chemotaxis induced by these chemokines. Conversely, binding to CCL25 was observed, but Evasin-4 did not inhibit CCL25-induced chemotaxis. Size-exclusion chromatography confirmed that Evasin-4 forms a complex with CCL2 and CCL18. In accordance with the standard properties of unmodified small proteins, Evasin-4 was rapidly cleared following in vivo administration. To enhance the in vivo half-life and optimize its potential as a therapeutic agent, Fc fusions of Evasin-4 were created. Both the N- and C-terminal fusions were shown to retain binding activity, with the C-terminal fusion showing a modest reduction in potency.

  • Animals
  • Carrier Proteins
  • Cell Line
  • Chemokines, CC/metabolism
  • Humans
  • Protein Binding
  • Receptors, Chemokine/metabolism
  • Ticks
  • Evasin
  • Chemokine-binding protein
  • Inflammation
Citation (ISO format)
DERUAZ, Maud et al. Evasin-4, a tick-derived chemokine-binding protein with broad selectivity can be modified for use in preclinical disease models. In: The FEBS journal, 2013, vol. 280, n° 19, p. 4876–4887. doi: 10.1111/febs.12463
Main files (1)
Article (Published version)
ISSN of the journal1742-464X

Technical informations

Creation02/26/2014 12:23:00 PM
First validation02/26/2014 12:23:00 PM
Update time03/14/2023 8:59:32 PM
Status update03/14/2023 8:59:31 PM
Last indexation01/16/2024 9:17:19 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack